| Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s proprietary drugs and drug candidates that have either received regulatory approval or are being developed by Co. or in collaboration with other pharmaceutical companies or independent investigators include: ONZEALD, a topoisomerase I inhibitor targeted for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule for moderate to severe chronic pain; NKTR-214, a CD122-biased immune-stimulatory cytokine targeted for oncology; NKTR-358 for autoimmune disease; NKTR-262 targeted for solid tumors; and NKTR-255 targeted for immuno-oncology. We show 42 historical shares outstanding datapoints in our coverage of NKTR's shares outstanding history.|
Understanding the changing numbers of NKTR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NKTR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NKTR by allowing them to research NKTR shares outstanding history
as well as any other stock in our coverage universe.